主要文件

查看所有文档

51261

(-)-儿茶素

Name: (-)-儿茶素
Brand: SIAL

puriss., ≥98.5% (HPLC)

别名:

(-)- 反 -3,3′,4′5,7-五羟基黄烷, (2S,3R)-2-（3,4-二羟基苯基）-3,4-二氢-1 (2H)-苯并吡喃-3,5,7-三醇

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₅H₁₄O₆

化学文摘社编号:

18829-70-4

分子量:

290.27

EC Number:

242-611-7

UNSPSC Code:

12352200

MDL number:

MFCD00135997

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

puriss.

assay

≥98.5% (HPLC)

storage temp.

2-8°C

SMILES string

O[C@@H]1Cc2c(O)cc(O)cc2O[C@H]1c3ccc(O)c(O)c3

InChI

1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15+/m1/s1

InChI key

PFTAWBLQPZVEMU-HIFRSBDPSA-N

说明

Still not finding the right product?

Explore all of our products under (-)-儿茶素

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors.

Woo Duck Seo et al.

Bioorganic & medicinal chemistry letters, 15(24), 5514-5516 (2005-10-06)

Chalcones 1-20, a new class of glycosidase inhibitors, were synthesized, and their glycosidase inhibitory activities were investigated. Non-aminochalcones 1-12 had no inhibitory activity, however, aminochalcones 13-20 had strong glycosidase (alpha-glucosidase, alpha-amylase, and beta-amylase) inhibitory activities. In particular, sulfonamide chalcones 17-20

Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies.

Christine A Larsen et al.

Journal of medicinal chemistry, 52(21), 6543-6545 (2009-10-21)

Most cancer deaths result from spread of the primary tumor to distant sites (metastasis). MET is an important protein for metastasis in multiple tumor types. Here we report on the ability of tea catechins to suppress MET activation in human

Catechin gallates are NADP+-competitive inhibitors of glucose-6-phosphate dehydrogenase and other enzymes that employ NADP+ as a coenzyme.

Eui Seok Shin et al.

Bioorganic & medicinal chemistry, 16(7), 3580-3586 (2008-03-04)

Recent studies have shown that glucose-6-phosphate dehydrogenase (G6PD) is an effectual therapeutic target for metabolic disorders, including obesity and diabetes. In this study, we used in silico and conventional screening approaches to identify putative inhibitors of G6PD and found that

查看所有相关文献